Results for tag: "5 Hydroxytryptamine Receptor 7"

The 5-Hydroxytryptamine Receptor 7 (5-HT7) is a G-protein coupled receptor (GPCR) that is involved in the regulation of various physiological processes in the central nervous system (CNS). It is a target for the development of drugs for the treatment of CNS disorders such as depression, anxiety, schizophrenia, and Alzheimer's disease. 5-HT7 agonists have been shown to have antidepressant-like effects in animal models, while 5-HT7 antagonists have been shown to have anxiolytic-like effects. The 5-HT7 market is a rapidly growing segment of the CNS drug market, with a number of companies developing drugs targeting this receptor. Companies are focusing on developing novel compounds that can modulate the 5-HT7 receptor in order to treat CNS disorders. These compounds include small molecules, peptides, and antibodies. Companies in the 5-HT7 market include AbbVie, AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more